TG Therapeutics, Inc. Announces Management Changes
June 23, 2021 at 06:05 am
Share
The Board of Directors of TG Therapeutics, Inc. has determined that it is in the Company’s best interests to designate a lead independent director. On June 16, 2021, the Board appointed Mr. Laurence Charney as lead independent director. Mr. Michael S. Weiss will continue to serve as Chairman. In connection with the appointment of Mr. Charney as lead independent director, Mr. Weiss’ title was changed from Executive Chairman and Chief Executive Officer to Chairman and Chief Executive Officer. Additionally, on June 18, 2021, effective as of June 30, 2021, Mr. Weiss and the Company agreed to terminate the Strategic Advisory Agreement (the “Advisory Agreement”) with Caribe BioAdvisors, LLC owned by Mr. Weiss to provide the services of Mr. Weiss as Chairman of the Board and as Executive Chairman.
TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates include Ublituximab (anti-CD20 mAb), TG-1701 (BTK inhibitor) and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Brutonâs tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It is the therapy to target both CD19, a B-cell specific market expressed across B-cell malignancies, and CD47. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
TG THERAPEUTICS, INC. 
